Biogen reports 82.5% stability in LEQEMBI study
Biogen (NASDAQ:BIIB) and Eisai reported that 82.5% of LEQEMBI patients remained stable or improved over 17 months.
Grafa Headlines
Headlines
Tech
Boeing delivers 171 commercial aircraft in second quarter
Boeing (NYSE:BA) delivered 171 commercial aircraft in 2Q26, led by 129 737s, bringing its first-half total to 314 units.
Tech
Nvidia H200 approvals expand to three Chinese firms
Three Chinese firms received U.S. approval to purchase advanced AI chips from Nvidia (NASDAQ:NVDA) and Advanced Micro Devices (NASDAQ:AMD), expanding the licensed customer group.
Tech
Meta faces AI layoff lawsuit from 26 employees
Meta Platforms (NASDAQ:META) was sued by 26 current and former employees who allege its AI-assisted layoff process disproportionately selected workers with disabilities or protected leave.
Tech
Bristow completes $105 million Berry Aviation acquisition
Bristow Group (NYSE:VTOL) completed its $105 million acquisition of Berry Aviation from Acorn Capital Management, expanding its government and special-mission aviation operations.
NextNRG June revenue rises 26% to $8.9 million
NextNRG (NASDAQ:NXXT) reported preliminary June 2026 revenue of $8.9 million, up 26%, while gross profit increased approximately 44% to $654,000.
Citigroup profit rises 45% on $24.8 billion revenue
Citigroup (NYSE:C) reported Q2 2026 net income of $5.83 billion, or $3.15 per share, as revenue rose 14% to $24.77 billion.
CervoMed selects 50 mg Phase 3 dose
CervoMed (NASDAQ:CRVO) reported new Phase 2b analyses linking neflamapimod benefits to low pTau181 levels and sufficient drug exposure in the 159-patient RewinD-LB trial.
Ranger Energy Services expands ECHO rig fleet with Hess Corporation contract
Ranger Energy Services (NYSE:RNGR) announced a new agreement to provide three additional ECHO hybrid workover rigs to Hess Corporation (a subsidiary of Chevron (NYSE:CVX)), marking a continued expansion of its electrified rig fleet.
Hemab Therapeutics presents positive sutacimig data
Hemab Therapeutics (NASDAQ:COAG) shared Phase 2 long-term extension data for its drug candidate sutacimig, which demonstrated sustained prophylactic bleed reduction across 34 patients with Glanzmann thrombasthenia.